Profile data is unavailable for this security.
About the company
Indaptus Therapeutics, Inc. is a clinical-stage biotechnology company, which specializes in cancer and viral infection treatments. The Company’s approach is based on the hypothesis that activation of both innate and adaptive immune cells and pathways and associated anti-tumor and anti-viral immune responses will require a multi-targeted package of immune system-activating signals that can be administered safely intravenously (i.v.). Its technology is composed of single strains of attenuated and killed, non-pathogenic, Gram-negative bacteria producing a multiple Toll-like receptor (TLR), Nucleotide oligomerization domain (NOD)-like receptor (NLR) and Stimulator of interferon genes (STING) agonist Decoy platform. The Company's lead clinical candidate is Decoy20. Its Decoy product candidates have also produced significant single agent activity against chronic hepatitis B virus (HBV) and chronic human immunodeficiency virus (HIV) infections in pre-clinical models.
- Revenue in USD (TTM)0.00
- Net income in USD-15.75m
- Incorporated2021
- Employees7.00
- LocationIndaptus Therapeutics Inc3 Columbus Circle, 15Th FloorNEW YORK 10019United StatesUSA
- Phone+1 (646) 427-2727
- Websitehttps://indaptusrx.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Kiora Pharmaceuticals Inc | 16.02m | 2.67m | 11.21m | 12.00 | -- | 0.3353 | 4.15 | 0.6999 | -7.76 | -7.76 | 6.61 | 11.14 | 0.5279 | -- | 7.16 | 1,335,000.00 | 10.54 | -70.52 | 11.20 | -81.86 | -- | -- | 19.98 | -2,040.61 | -- | -- | 0.00 | -- | -- | -- | 3.97 | -- | -- | -- |
| BioRestorative Therapies Inc | 174.10k | -8.00m | 11.39m | 11.00 | -- | 1.06 | -- | 65.44 | -1.22 | -1.22 | 0.029 | 1.56 | 0.0118 | -- | 6.65 | 15,827.27 | -54.42 | -192.11 | -68.75 | -329.32 | 47.45 | -- | -4,597.79 | -19,116.15 | -- | -- | 0.00 | -- | 21.70 | 5.61 | 43.67 | -- | 67.77 | -- |
| Nascent Biotech Inc | 0.00 | -1.92m | 11.45m | -- | -- | -- | -- | -- | -0.012 | -0.012 | 0.00 | -0.003 | 0.00 | -- | -- | -- | -1,256.81 | -708.50 | -- | -- | -- | -- | -- | -589.83 | -- | -- | -- | -- | -- | -- | 25.47 | -- | -- | -- |
| Biora Therapeutics Inc | 860.00k | -86.81m | 11.80m | 58.00 | -- | -- | -- | 13.73 | -55.72 | -55.63 | 0.2398 | -24.85 | 0.0253 | -- | 1.05 | 14,827.59 | -255.56 | -122.84 | -- | -369.01 | -- | -- | -10,094.19 | -415.10 | -- | -- | -- | -- | -98.69 | -87.44 | -154.63 | -- | -53.68 | -- |
| Imunon Inc | 0.00 | -18.08m | 12.02m | 33.00 | -- | 2.08 | -- | -- | -1.92 | -1.92 | 0.00 | 0.398 | 0.00 | -- | -- | 0.00 | -94.15 | -50.18 | -132.90 | -60.27 | -- | -- | -- | -5,725.88 | -- | -- | 0.00 | -- | -100.00 | -- | 45.64 | -- | 26.69 | -- |
| Turnstone Biologics Corp | 0.00 | -74.70m | 12.07m | 82.00 | -- | 0.2021 | -- | -- | -3.49 | -3.49 | 0.00 | 2.58 | 0.00 | -- | -- | 0.00 | -98.52 | -- | -127.31 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -73.66 | -- | -78.05 | -- | -- | -- |
| Indaptus Therapeutics Inc | 0.00 | -15.75m | 12.34m | 7.00 | -- | 1.68 | -- | -- | -1.86 | -1.86 | 0.00 | 0.7209 | 0.00 | -- | -- | 0.00 | -108.73 | -66.55 | -126.30 | -81.23 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -7.68 | -- | -- | -- |
| Cardio Diagnostics Holdings Inc | 39.14k | -8.77m | 12.41m | 7.00 | -- | 3.08 | -- | 317.11 | -0.4899 | -0.4899 | 0.0021 | 0.1319 | 0.0073 | -- | 9.13 | 5,591.43 | -163.16 | -- | -268.73 | -- | -- | -- | -22,414.13 | -- | -- | -9.32 | 0.0295 | -- | 1,696.84 | -- | -79.72 | -- | -- | -- |
| Oncotelic Therapeutics Inc | 70.00k | -1.24m | 12.59m | 22.00 | -- | 1.04 | -- | 179.92 | -0.0031 | -0.0031 | 0.0002 | 0.0299 | 0.0023 | -- | 3.69 | 3,181.82 | -5.02 | -25.03 | -11.26 | -48.76 | -- | -- | -2,147.66 | -1,692.93 | -- | -0.5167 | 0.5228 | -- | -- | -- | -255.12 | -- | -- | -- |
| Protext Mobility Inc | 750.00 | -2.21m | 13.19m | 4.00 | -- | -- | -- | 17,582.44 | -0.4692 | -0.4692 | 0.00001 | -0.0102 | 0.0405 | -- | -- | -- | -9,400.97 | -1,587.94 | -- | -- | 86.67 | -530.19 | -232,392.00 | -17,498.83 | 0.0002 | -1.36 | -- | -- | -93.98 | -63.09 | 27.35 | -- | -- | -- |
| Biomx Inc | 0.00 | -26.25m | 13.22m | 58.00 | -- | -- | -- | -- | -0.4575 | -0.4575 | 0.00 | 0.3929 | 0.00 | -- | -- | 0.00 | -47.79 | -- | -57.76 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 7.59 | -- | -- | -- |
| Apollomics Inc | 0.00 | -57.11m | 13.22m | 45.00 | -- | 0.6337 | -- | -- | -0.568 | -0.568 | 0.00 | 0.1892 | 0.00 | -- | -- | 0.00 | -107.81 | -- | -144.29 | -- | -- | -- | -- | -- | -- | -- | 0.185 | -- | -- | -- | 28.33 | -- | -- | -- |
| OpGen Inc | 1.96m | -22.39m | 13.37m | 100.00 | -- | -- | -- | 6.80 | -20.01 | -20.01 | 1.66 | -8.65 | 0.1553 | -- | 6.09 | -- | -176.99 | -87.95 | -15,455.17 | -127.65 | 3.15 | 15.42 | -1,139.66 | -794.78 | -- | -20.25 | -- | -- | 31.11 | 3.02 | 12.38 | -- | 40.20 | -- |
| Evaxion Biotech A/S - ADR | 3.30m | -11.46m | 13.49m | 49.00 | -- | -- | -- | 4.10 | -16.80 | -16.80 | 0.8311 | -- | -- | -- | -- | 67,244.90 | -- | -100.11 | -- | -131.65 | -- | -- | -347.86 | -131,560.30 | -- | -- | -- | -- | -- | -- | 4.51 | -- | 65.53 | -- |
| Pharmacyte Biotech Inc | 0.00 | 4.50m | 13.52m | 2.00 | 3.48 | 0.2847 | 3.01 | -- | 0.5058 | 0.5058 | 0.00 | 6.87 | 0.00 | -- | -- | 0.00 | 35.90 | -7.42 | 38.19 | -7.68 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -299.38 | -- | -- | -- |
Data as of Nov 12 2024. Currency figures normalised to Indaptus Therapeutics Inc's reporting currency: US Dollar USD
5.83%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 30 Jun 2024 | 256.27k | 2.51% |
| The Investment House LLCas of 30 Sep 2024 | 99.98k | 0.98% |
| Geode Capital Management LLCas of 30 Jun 2024 | 59.31k | 0.58% |
| Strategy Asset Managers LLCas of 30 Sep 2024 | 45.34k | 0.45% |
| Pine Valley Investments LLCas of 30 Jun 2024 | 44.09k | 0.43% |
| Renaissance Technologies LLCas of 30 Jun 2024 | 26.60k | 0.26% |
| Vivaldi Capital Management LPas of 30 Jun 2024 | 24.00k | 0.24% |
| Citadel Securities LLCas of 30 Jun 2024 | 22.21k | 0.22% |
| SSgA Funds Management, Inc.as of 30 Jun 2024 | 13.07k | 0.13% |
| Tower Research Capital LLCas of 30 Jun 2024 | 4.10k | 0.04% |
More ▼
Data from 30 Jun 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
